Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. Academic Article uri icon

Overview

publication date

  • July 24, 2024

Identity

PubMed Central ID

  • PMC11269363

Digital Object Identifier (DOI)

  • 10.1002/hem3.136

PubMed ID

  • 39055646

Additional Document Info

volume

  • 8

issue

  • 7